Covid19 Clinical Trial
— SPEED-COVIDOfficial title:
Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study
| NCT number | NCT04872699 |
| Other study ID # | SPEED-COVID19 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | April 22, 2021 |
| Est. completion date | May 31, 2022 |
The aim of this study is to evaluate the prevalence of COVID-19 among the residents and geriatric inpatients of the care facilities attached to the Centre Hospitalier Sud Essonne (a general hospital located in Ile-de-France, France), and the factors that are likely to influence this prevalence.
| Status | Recruiting |
| Enrollment | 150 |
| Est. completion date | May 31, 2022 |
| Est. primary completion date | May 31, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - residents of the dependant care facility for the elderly - inpatients of the long-term care unit - from march, 2020 to december, 2021 Exclusion Criteria: - opposition to participate in this study |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Hospitalier Sud Essonne | Étampes | Essonne |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Sud Essonne |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | General prevalence of COVID-19 | measures the prevalence of COVID-19 among the residents and geriatric inpatients, defined as resident and patients with positive serologic or RT-PCR test | Through the study completion, an average of 12 months | |
| Secondary | Number of asymptomatic residents/inpatients | no RT-PCR test or negative RT-PCR test and positive serologic test,
positive RT PCR and no symptoms. |
Through study completion, an average of 12 months | |
| Secondary | Number of symptomatic residents/inpatients | Positive RT-PCR test or serologic test with symptoms | Through study completion, an average of 12 months | |
| Secondary | Number of residents/inpatients with severe form of COVID-19 which led to an hospitalization | Positive RT-PCR test or serologic test and hospitalization | Through study completion, an average of 12 months | |
| Secondary | Number of residents/inpatients infected with COVID-19 and hospitalized in a critical care unit | Positive RT-PCR test or serologic test and hospitalization in critical care unit | Through study completion, an average of 12 months | |
| Secondary | Number of residents/inpatients infected with COVID-19 and deceased | Positive RT-PCR test or serologic test and deceased | Through study completion, an average of 12 months | |
| Secondary | Number of residents/inpatients vaccinated against COVID-19 | Positive RT-PCR test or serologic test and vaccinated with any authorized vaccine | Through study completion, an average of 12 months | |
| Secondary | Influencing factors of the prevalence of COVID-19 among residents/inpatients | age
sex comorbidities the context of the infection with COVID-19 vaccinated or not |
Through study completion, an average of 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |